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Cellular senescence acts as a potent mechanism of
tumor suppression; however, its functional contribu-
tion to noncancer pathologies has not been exam-
ined. Here we show that senescent cells accumulate
in murine livers treated to produce fibrosis, a precur-
sor pathology to cirrhosis. The senescent cells are
derived primarily from activated hepatic stellate
cells, which initially proliferate in response to liver
damage and produce the extracellular matrix depos-
ited in the fibrotic scar. In mice lacking key senes-
cence regulators, stellate cells continue to prolifer-
ate, leading to excessive liver fibrosis. Furthermore,
senescent activated stellate cells exhibit gene ex-
pression profile consistent with cell-cycle exit, re-
duced secretion of extracellular matrix components,
enhanced secretion of extracellular matrix-degrad-
ing enzymes, and enhanced immune surveillance.
Accordingly natural killer cells preferentially kill sen-
escent activated stellate cells in vitro and in vivo,
thereby facilitating the resolution of fibrosis. There-
fore, the senescence program limits the fibrogenic
response to acute tissue damage.
INTRODUCTION
Cellular senescence is a stable form of cell-cycle arrest that may
limit the proliferative potential of premalignant cells (Campisi and
d’Adda di Fagagna, 2007). Initially defined by the phenotype of
human fibroblasts undergoing replicative exhaustion in culture
(Hayflick and Moorhead, 1961), senescence can be triggered
in many cell types in response to diverse forms of cellular dam-
age or stress (Campisi and d’Adda di Fagagna, 2007; Serrano
et al., 1997). Although once considered a tissue culture phenom-
enon, recent studies demonstrate that cellular senescenceimposes a potent barrier to tumorigenesis and contributes to
the cytotoxicity of certain anticancer agents (Braig et al., 2005;
Chen et al., 2005; Collado et al., 2005; Michaloglou et al.,
2005; Schmitt et al., 2002). Interestingly, senescent cells have
also been observed in certain aged or damaged tissues;
however, the functional contribution of cellular senescence to
noncancer pathologies has not been examined.
Senescent cells display a large flattened morphology and ac-
cumulate a senescence-associated b-galactosidase (SA-b-gal)
activity that distinguishes them from most quiescent cells (Cam-
pisi and d’Adda di Fagagna, 2007). In addition, they often down-
regulate genes involved in proliferation and extracellular matrix
production and upregulate inflammatory cytokines and other
molecules known to modulate the microenvironment or immune
response (Campisi and d’Adda di Fagagna, 2007; Schnabl et al.,
2003). Consistent with the role of cellular senescence as a barrier
to malignant transformation, senescent cells activate the p53
and p16/Rb tumor suppressor pathways (Campisi and d’Adda
di Fagagna, 2007; Collado et al., 2007). p53 promotes senes-
cence by transactivating genes that inhibit proliferation, includ-
ing the p21/Cip1/Waf1 cyclin-dependent kinase inhibitor and
miR-34 class of microRNAs (He et al., 2007). In contrast,
p16INK4a promotes senescence by inhibiting cyclin-dependent
kinases 2 and 4, thereby preventing Rb phosphorylation and al-
lowing Rb to promote a repressive heterochromatin environment
that silences certain proliferation-associated genes (Narita et al.,
2003). Although the p53 and p16/Rb pathways act in parallel to
promote senescence, their relative contribution to the program
can be cell type dependent (Campisi and d’Adda di Fagagna,
2007).
Although senescent cells can remain viable in culture indefi-
nitely, their fate in tissue is not well characterized. On one
hand, benign melanocytic nevi (moles) are highly enriched for
senescent cells yet can exist in skin throughout a lifetime (Micha-
loglou et al., 2005), implying that senescent cells can be stably
incorporated into tissue. On the other hand, liver carcinoma cells
induced to undergo senescence in vivo can be cleared by
components of the innate immune system leading to tumorCell 134, 657–667, August 22, 2008 ª2008 Elsevier Inc. 657
regression (Xue et al., 2007). Therefore, in some circumstances,
senescent cells can turn over in vivo.
Liver cirrhosis is a major health problem worldwide (Bataller
and Brenner, 2005) and the 12th most common cause of death
in the United States (NCHS, 2004). Liver fibrosis acts as a precur-
sor to cirrhosis and is triggered by chronic liver damage pro-
duced by hepatitis virus infection, alcohol abuse, or nonalcoholic
steatohepatitis (NASH, fatty liver disease). The hepatic stellate
cell (HSC, also called Ito cell) is a key cell type that contributes
to liver fibrosis. Upon liver damage, HSCs become ‘‘acti-
vated’’—i.e., they differentiate into myofibroblasts, proliferate,
and produce the network of extracellular matrix that is the hall-
mark of the fibrotic scar (Bataller and Brenner, 2005). Following
acute damage, activated HSCs probably support hepatocyte
proliferation and organ repair (Passino et al., 2007); however,
during chronic damage the excessive extracellular matrix
produced by these cells disrupts liver cytoarchitecture leading
eventually to cirrhosis and liver failure (Bataller and Brenner,
2005).
SA-b-gal-positive cells have been observed in cirrhotic livers
of human patients (Wiemann et al., 2002), although the nature
of these putative senescent cells and their impact on liver biology
are not known. To study the potential role of cellular senescence
in liver cirrhosis, we used a well-established mouse model where
fibrosis is produced by chronic treatment with CCl4, a liver-dam-
aging agent (Bataller and Brenner, 2005). We examined the ac-
cumulation of senescent cells following CCl4 treatment, as well
as their fate following CCl4 withdrawal. We also examined the
course of liver fibrosis in mutant strains of mice where the senes-
cence program was attenuated by disabling the p53 and/or p16/
Rb pathways. Unexpectedly, our results establish that cellular
Figure 1. Senescent Cells Are Present in
Fibrotic Livers
(A) CCl4 (fibrotic) but not vehicle (control) treated
livers exhibit fibrotic scars (evaluated by H&E
and Sirius Red staining). Multiple cells in the areas
around the scar stain positively for senescence
markers (SA-b-gal and p16 staining).
(B) The cells around the scar also coexpress se-
nescence markers p21, p53, and Hmga1 and are
distinct from proliferating Ki67-positive cells.
Numbers in the lower left corner indicate number
of double-positive cells (yellow) out of p21-posi-
tive cells (green). Scale bars are 50 mm.
senescence limits the extent of fibrosis
following liver damage and underscore
the interplay between senescent cells
and the tissue microenvironment.
RESULTS
Senescent Activated Stellate Cells
Accumulate in the Cirrhotic Liver
To investigate the relationship between
fibrosis and cellular senescence, we sub-
jected 7- to 9-week-old female mice to
a six week treatment with CCl4, a chemical widely used to induce
fibrosis in experimental animals (Bataller and Brenner, 2005).
This protocol produced fibrosis as assessed by staining with
Hematoxylin-Eosin and Sirius Red, which directly marks the
extracellular matrix deposited by activated HSCs (Figure 1A).
Approximately 2% of the liver was Sirius Red positive as as-
sessed by quantitative laser scanning cytometry, representing
a 3- to 4-fold increase over untreated controls. Furthermore,
CCl4 treatment produced a dramatic expansion of activated
HSCs, which were visualized by immunofluorescence staining
of liver sections for the activated HSC markers desmin and
a-smooth muscle actin (aSMA) (data not shown, see also
Figure 2).
To identify senescent cells in situ, we stained liver sections
from CCl4 and vehicle-treated (control) mice for a panel of senes-
cence-associated markers, including SA-b-gal and proteins
such as p16, p21, p53, and Hmga1, which have been causally
linked to the senescence program (Collado et al., 2007; Narita
et al., 2006; Serrano et al., 1997). Cells staining positive for SA-
b-gal and each senescence-associated protein accumulated in
fibrotic livers and were invariably located along the fibrotic scar
(Figure 1). These cells typically expressed multiple senescence
markers and were not proliferating (only cells with nuclear stain-
ing for p21, p53, and Hmga1 were considered positive). For ex-
ample, of the p21-positive cells identified in fibrotic livers, 87%
were positive for p53 immunostaining and 90% were positive
for Hmga1 staining (Figure 1B), whereas only 8% coexpressed
the proliferation-association marker Ki67 despite a general
increase in the frequency of Ki67-positive cells (Figure 1B). Of
note, these senescence markers were not expressed in control
livers (Figure 1B, data not shown). Moreover, senescent cells658 Cell 134, 657–667, August 22, 2008 ª2008 Elsevier Inc.
also accumulated in livers derived from mice treated with DDC
(3,5-diethoxycarbonyl-1,4-dihydrocollidine), another agent that
produces liver fibrosis and cirrhosis (data not shown).
Although hepatocytes represent the most abundant cell type
in the liver, the location of senescent cells along the fibrotic
scar in both human (Wiemann et al., 2002) and mouse
(Figure 1B) livers raised the possibility that these cells were de-
rived from activated HSCs, which initially proliferate following
liver damage and are responsible for much of the extracellular
matrix production in fibrosis. Accordingly, in mouse fibrotic liver
sections, the cells that stained positive for the senescence-asso-
ciated markers p53 and Hmga1 were also positive for the HSC
markers desmin and aSMA, and, in serial sections, most SA-b-
gal-positive cells also expressed aSMA (Figure 2B). Similarly,
in serial sections obtained from human cirrhotic livers, cells
expressing the senescence markers p21 and p16 colocalized
with those expressing aSMA (Figure 2C). Therefore, senescent-
activated HSCs accumulate in fibrotic livers.
Fibrosis Progression Is Restricted by an Intact
Senescence Machinery
Hepatic stellate cells initially proliferate in response to liver dam-
age, and so it was not obvious how their senescence would
ultimately influence the progression of fibrosis. Since p53 con-
tributes to cellular senescence in most murine tissues (Collado
et al., 2007), cells derived from mice lacking p53 often show an
enhanced proliferative capacity in culture (Sherr, 1998). To eval-
Figure 2. Senescent Cells Are Derived from
Activated HSCs
(A) Senescent cells, identified by p53- and Hmga1-
positive staining, express activated HSC markers
Desmin and aSMA. Upper panel: Hmga1-positive
nuclei (red arrows) and Desmin cytoplasmic stain-
ing (green arrows) in same cells. Lower panel:
p53-positive nuclei (green arrows) and aSMA
(red arrows) cytoplasmic staining in same cells.
(B) Senescent cells, identified by SA-b-gal, stain
positive for HSC marker aSMA on serial sections
of mouse fibrotic liver.
(C) Senescent cells, identified by p21 or p16, stain
positive for HSC marker aSMA on serial sections
of human fibrotic liver. p21- and p16-positive cells
are not present in normal liver sections.
uate the biological impact of senescence
on liver fibrosis, we initially compared the
histopathology of livers obtained from
wild-type (WT) and p53/ mice treated
with CCl4. After 6 weeks, livers were
examined for fibrosis using Sirius Red
staining and expression of Tgfb1, a major
cytokine upregulated during fibrosis
progression (Bataller and Brenner, 2005).
Surprisingly, livers derived from p53/
mice contained significantly more fibrotic
tissue relative to WT controls (Figures 3A
and 3B and data not shown, p = 0.008)
and also displayed an increase in Tgfb1
expression (Figure S1 available online). This increase in fibrosis
was associated with an aberrant expansion of activated HSCs
as assessed by aSMA expression as a surrogate marker for
the abundance of this cell type (Figures 3C and S1). Conversely,
livers derived from p53/ mice treated with CCl4 showed more
proliferating cells (Figure S2) and a decrease in SA-b-gal staining
compared to WT controls (Figure 3A). These observations sug-
gest that, in the absence of p53, liver damage produces fewer
senescent cells, and a corresponding increase in activated
HSCs, extracellular matrix deposition, and fibrosis.
In many cell types, both the p53 and the p16/Rb pathways
contribute to senescence such that cells lacking either pathway
alone retain a residual senescence response (Serrano et al.,
1997). In fact, livers derived from p53/ mice treated with
CCl4 still showed some increase in SA-b-gal-positive cells and
retained their ability to upregulate p16 (Figure 3A). Moreover,
CCl4 treated livers from INK4a/ARF
/ mice also showed only
a partial reduction in senescence (corresponding to an increase
in HSCs [Figure 3C] and fibrosis [data not shown]) and still up-
regulated p53 (data not shown). To determine the impact of
disrupting both loci on senescence and fibrosis in the liver, we
produced p53/;INK4a/ARF/ compound mutant mice. Since
less than 5% of the female double mutant mice reached adult-
hood, only male animals were used in these experiments. Of
note, male mice develop more severe fibrosis than females
(compare Figure 4B to Figure 4C; see also Shimizu et al., 2007),
making comparisons within the same sex essential.Cell 134, 657–667, August 22, 2008 ª2008 Elsevier Inc. 659
Figure 3. Intact Senescence Pathways Are
Required to Restrict Fibrosis Progression
(A) Mice lacking p53 develop pronounced fibrosis
following CCl4 treatment, as identified by Sirius
Red staining. Livers from wild-type (WT) or p53/
mice treated with CCl4 were harvested and sub-
jected to Sirius Red and SA-b-gal staining, and
p16 immunocytochemistry, and p53 immunofluo-
rescence analysis. There are fewer senescent
cells in mutant livers, as identified by SA-b-gal
activity.
(B) Quantification of fibrosis based on Sirius Red
staining. Values are means + standard error of
the mean (SEM). Fibrotic area in mutant animals
was compared to WT of corresponding time point
using Student’s t test (*p < 0.05, **p < 0.01).
(C) Immunoblot showing expression of aSMA in
liver of mice treated with CCl4. There are more ac-
tivated HSCs in the p53 and INK4a/ARF mutant
mice than in WT as shown by higher protein
expression of the activated HSC marker aSMA
analyzed by immunoblot. Two upper panels repre-
sent different exposures times for aSMA.
(D) BrdU incorporation over 2 hr in activated HSCs
derived from WT and DKO mice. Values are
means + SEM.
(E) SA-b-gal activity and fibrosis (evaluated by
Sirius Red) in livers from WT and p53/;INK4a/
ARF/ (DKO) mice treated with CCl4. Scale bars
are 100 mm.
(F) Fibrosis was quantified as described before.
There is stronger fibrosis in mice lacking both
p53 and INK4a/ARF. Values are means + SEM.
(G) Expression of aSMA in WT and DKO fibrotic
livers was evaluated by immunoblot.
(H) Fibrosis in TRE-shp53 (Tg) and GFAP-tTA;TRE-
shp53 (DTg) was quantified as described before.
Values are means + SEM.
(I) Expression of aSMA in Tg and DTg fibrotic livers
was evaluated by immunoblotting.
(J) There are more proliferating activated HSCs
(Ki67- and aSMA-positive) in DTg livers derived
from mice treated with CCl4.Consistent with the predicted consequences of p53 and
INK4a/ARF inactivation on senescence, isolated HSCs from
double knockout livers did not senesce in culture, showing
much less SA-b-gal activity and much more BrdU incorporation
compared to WT cells, which senesced after a few passages
(Figures 3D and S3; data not shown). Livers derived from CCl4
treated mice lacking both p53 and INK4a/ARF developed severe
fibrosis when compared to WT animals, showing a greater than
50% increase in fibrotic area, wider fibrotic scars, and substan-
tially more scar branching (Figures 3E and 3F). Moreover, double
mutant livers contained few SA-b-gal-positive cells (Figure 3E)
and harbored a large increase in activated HSCs as determined
by aSMA protein (Figure 3G) and mRNA (data not shown, 35-fold
relative to controls, p = 0.02) expression. Double knockout ani-
mals also developed clearly visible ascites, one of the clinical
manifestations of cirrhosis, resulting in significantly wider abdo-
mens compared to controls (Figure S4, p = 0.006). Therefore,660 Cell 134, 657–667, August 22, 2008 ª2008 Elsevier Inc.activated HSCs lacking both the p53 and INK4a/ARF genes
(and thus the ARF/p53 and p16/Rb pathways) fail to senesce
and inappropriately expand in response to chronic liver damage,
leading to more extracellular matrix production and fibrosis.
To confirm that the above phenotypes were a result of im-
paired senescence in activated HSCs and not other liver cell
types, we specifically suppressed p53 expression in HSCs and
examined the extent of liver fibrosis and activated HSC prolifer-
ation after CCI4 treatment. Transgenic mice harboring a tetracy-
cline response element (TRE) driven short-hairpin RNA (shRNA)
capable of efficiently suppressing p53 expression (Dickins
et al., 2007) were crossed to mice harboring a tTA (tetracy-
cline-controlled transactivator) transgene expressed from the
Gfap promoter (Wang et al., 2004), which, in the liver, is HSC spe-
cific (Bataller and Brenner, 2005; Zhuo et al., 2001). As the tTA
transactivaor binds the TRE promoter in the absence of tetra-
cycline, double-transgenic mice (DTg) should constitutively
express the p53 shRNA, which proved to be the case (Figure S5).
Consistent with observations in p53 null animals, double-trans-
genic mice where p53 was suppressed specifically in HSCs
developed significantly more fibrosis than controls (Figure 3H,
p = 0.0009); moreover, immunofluorescence studies revealed
that their livers contained more proliferating HSCs (Ki67- and
aSMA-positive) (Figures 3I and 3J). Apparently, the senescence
of activated stellate cells limits fibrotic progression.
Cellular Senescence Facilitates the Reversion
of Fibrosis
Although the architectural changes that accompany cirrhosis are
considered irreversible, it is now evident that fibrosis in patients,
Figure 4. An Intact Senescence Response Promotes Fibrosis
Resolution
Mice were treated with CCl4 for 6 weeks and livers were harvested 10 and 20
days following cessation of the treatment. (A) There is a significant retention of
fibrotic tissue in p53/ livers as compared to WT ones as identified by Sirius
Red staining at the 10 and 20 days time points. SA-b-gal staining shows se-
nescent cells at fibrotic liver 10 and 20 days after cessation of fibrogenic treat-
ment. Senescent cells are eliminated from the liver during reversion of fibrosis.
Quantification of fibrosis in WT andp53/ (B) or WT andp53/;INK4a/ARF/
(DKO) (C) mice based on Sirius Red staining of livers is shown. Values are
means + SEM; fibrotic area in mutant animals was compared to WT of corre-
sponding time point using Student’s t test (*p < 0.05, **p < 0.01, ***p < 0.001).even in more advanced stages, can regress following eradication
of the disease trigger (Bataller and Brenner, 2005). Accordingly,
liver fibrosis in WT animals resolved within 10 days after stop-
ping CCl4 treatment and was almost undetectable by 20 days
(Figure 4A). The frequency of senescent cells in WT livers
declined with the reversion of fibrosis, as did the number of
HSCs, such that no SA-b-gal-positive cells were detected in 20
day post-treatment livers and the amount of aSMA present dra-
matically declined. In marked contrast, activated HSCs were
clearly retained in livers from p53/ mice at 20 days post-treat-
ment, and this correlated with an impairment in fibrotic reversion
(Figures 4A and 4B, p = 0.014, p = 0.006, 10 or 20 days after the
treatment, respectively). Even more fibrotic lesions and activated
HSCs were retained in p53/;INK4a/ARF/ mice at this time
point (Figures 4C and S6).
Consistent with the impaired clearance of fibrotic tissue in the
absence of p53, livers derived from p53/ animals displayed
much higher levels of TGFb and aSMA following CCl4 with-
drawal compared to controls, implying that they maintained
greater fibrogenic signaling and more activated HSCs
(Figure S1). p53/ livers also retained more proliferating (Ki67-
positive) cells than did WT controls (Figure S2), suggesting that
p53-deficient activated HSCs can bypass the senescence re-
sponse, continue to proliferate, and deposit extracellular matrix
in the scars. We therefore hypothesized that senescence limits
proliferation of activated HSCs and facilitates their clearance
from the liver.
Senescent Activated HSCs Upregulate the Expression
of Immune Modulators
As a first step toward defining how activated stellate cells un-
dergo senescence and are cleared from tissue, we compared
the transcriptional profiles of cultured primary human activated
HSCs that were proliferating or triggered to senesce by treat-
ment with a DNA-damaging agent, etoposide. Like IMR-90 nor-
mal diploid fibroblasts, a cell type in which senescence has been
studied extensively, activated HSCs stopped proliferating, accu-
mulated SA-b-gal activity, and acquired senescence-associated
heterochromatic foci within several days of etoposide treatment
yet retained the activated HSC markers aSMA, GFAP, and
Vimentin (Figure 5A). Thus, by several criteria, etoposide-treated
activated HSCs undergo senescence.
Gene expression profiling of two different activated HSC prep-
arations was performed using Affymetrix Human Genome U133
Plus 2.0 Arrays, and the differentially expressed genes analyzed
using Gene Ontology (GO) to identify biological processes and
pathways that were altered in an unbiased way. Consistent
with the proliferative arrest that accompanies senescence, the
most significantly overrepresented ‘‘Biological Process’’ term
among downregulated genes was ‘‘cell cycle’’ (Table S1, p =
1.72E-21) and included genes necessary for cell-cycle progres-
sion, such as CDKN3, CyclinB (CCNB1, CCNB2), CDC20, and
the E2F target genes CDC2 (CDC2), CyclinA2 (CCNA2), and
Thymidine kinase (TK1). Genes encoding extracellular matrix
components were also significantly overrepresented among
downregulated genes, including those linked to ‘‘extracellular
matrix’’ (Cellular Component term) and ‘‘extracellular matrixCell 134, 657–667, August 22, 2008 ª2008 Elsevier Inc. 661
Figure 5. Senescent Activated HSCs Downregulate Extracellular Matrix Production and Upregulate Genes that Modulate Immune
Surveillance
(A) Activated HSCs treated with a DNA-damaging agent, etoposide (Senescent), and intact proliferating cells (Growing) were stained for SA-b-gal activity and for
expression of HSC markers (aSMA, GFAP, Vimentin) by immunofluorescent staining (green) and counterstained with DAPI (blue). Insets: Higher magnification
of DAPI-stained nuclear DNA shows presence of heterochromatic foci in senescent cells. Arrowheads point to nuclei shown in the insets.
(B) Quantitative RT-PCR analysis reveals decreased expression of extracellular matrix components in senescent activated HSCs. Values are means + SEM.
(C) Extracellular matrix-degrading matrix metalloproteinases are upregulated in senescent activated HSCs. Values represent the average of duplicate samples
from microarrays.
(D) Quantitative RT-PCR analysis reveals increased expression of cytokines, adhesion molecules, and NK cell receptor ligands in senescent activated HSCs
and IMR-90 cells as compared to growing cells. Values are means + SEM.structural constituent’’ (Molecular Function term) (p = 3.44E-6
and p = 1.75E-6, respectively). Interestingly, Collagens type I,
III, IV and Fibronectin are constituents of the fibrotic scar (Batal-
ler and Brenner, 2005), and most of these genes were downregu-
lated on our microarray (Figure S7) and quantitative RT-PCR
analyses (Figure 5B). These observations suggest that the se-
nescence program limits both the proliferative and fibrogenic
potential of activated HSCs.
Senescent human fibroblasts also show a pattern of gene ex-
pression that involves upregulation of secreted proteases, prote-
ase modulators, growth factors, and cytokines, often referred to
as the ‘‘senescence-associated secretory phenotype’’ (Campisi
and d’Adda di Fagagna, 2007). Similarly, senescent activated
HSCs upregulate matrix metalloproteinases, which have fibro-
lytic activity (Figure 5C). Moreover, these cells upregulate genes
related to ‘‘extracellular region’’ and ‘‘cytokine activity’’ (p =662 Cell 134, 657–667, August 22, 2008 ª2008 Elsevier Inc.4.18E-12, p = 1.98E-10, respectively). The most significantly
overrepresented Biological Process term among upregulated
genes was ‘‘immune response’’ (p = 2.84E-10) and, accordingly,
the only overrepresented KEGG pathway among upregulated
genes was ‘‘cytokine-cytokine receptor interaction’’ (p =
6.24E-4, Table S1, Figure S8).
Many of the genes upregulated in senescent activated HSCs
encoded cytokines or receptors that potentiate natural killer
(NK) cell function. For example, as confirmed by RT-QPCR,
MICA, the ligand of the NK cell receptor NKG2D, was upregu-
lated in senescent activated HSCs as well as IMR-90 cells
triggered to senesce by replicative exhaustion, expression of on-
cogenic Ras, or etoposide treatment (Figure 5D). Additionally,
the cytokine IL8, the NKG2D receptor ligand ULBP2, and the
adhesion moleculeCD58 (which mediates NK-target cell interac-
tions) were also upregulated in both senescent activated HSCs
and IMR-90 cells (Figure 5D). Thus, senescent activated HSCs
upregulate genes predicted to enhance immune surveillance.
Immune Cells Are Found in Proximity to Senescent Cells
in Fibrotic Livers
The data described above raise the possibility that senescence
might limit liver fibrosis by downmodulating extracellular matrix
production, upregulating extracellular matrix-degrading en-
zymes, and stimulating immune clearance of activated HSCs.
NK cells are a major component of the innate immune system
that recognize tumors, viruses, and MHC mismatched bone
marrow grafts (Raulet and Vance, 2006). These cells can directly
lyse target cells and influence killing by components of adaptive
immune system, including T cells (Raulet and Vance, 2006). Dur-
ing liver cirrhosis, NK cells and other immune cell types migrate
into the fibrotic scar, creating an inflammatory environment
(Bataller and Brenner, 2005; Muhanna et al., 2007). Accordingly,
we noted an accumulation of various immune cells in fibrotic
livers by flow cytometry (data not shown). Using electron micros-
copy to identify cells by morphological characteristics together
with immunofluorescence-based immunophenotyping, we ob-
served activated lymphocytes (including NK cells), macro-
phages, and neutrophils adjacent to HSCs in fibrotic liver tissue
from CCl4-treated mice but not normal controls (Figure 6A).
These immune cells were typically in close proximity to cells
expressing the senescent markers p53, p21, and Hmga1
(Figure 6B). These data, together with our expression analyses,
Figure 6. Immune Cells Recognize Senescent Cells
(A) Immune cells are adjacent to activated HSCs in vivo as identified by
electron microscopy of normal and fibrotic mouse livers. Immune cells
(lp: lymphocytes, mf: macrophage, np: neutrophil) localize adjacent
to activated HSC. Scale bar is 5 mm.
(B) Immune cells identified by CD45R (CD45) reside in close proximity
to senescent cells (identified by p21, p53, and Hmga1) in mouse
fibrotic liver.
(C and D) Senescent can be recognized by immune cells in vitro. Im-
ages are from timelapse microscopy of the same field at start (0) and
10 hr after presenting interaction between NK cells (uncolored) and
growing (C) or senescent (D) IMR-90 (pseudocolored, green) cells.
Original images and time points are presented in Figure S4. Scale
bar is 100 mm.
(E and F) Human NK cell line, YT, exhibits preferential cytotoxicity
in vitro toward senescent activated HSCs (E) or senescent IMR-90
cells (F) compared to growing cells. In IMR-90 cells senescence was
induced by DNA damage, extensive passaging in culture, or infection
with oncogenic rasV12. Both uninfected and empty vector-infected
growing cells were used as controls. At least three independent
experiments were performed in duplicates. Cytotoxicity values based
on crystal violet quantification at OD595 are shown; values are
means + SEM, **p < 0.005 using Student’s t test.
raise the possibility that senescent cells produce signals
that attract immune cells into fibrotic lesions.
Senescent Stellate Cells Are Selectively Targeted
by NK Cells
We previously showed that NK cells can be required for
the clearance of senescent tumor cells in vivo (Xue
et al., 2007). As senescent activated HSCs and IMR-90
cells were found to express all of the components necessary
for NK cell recognition, we tested whether they could be selec-
tively killed by NK cells in vitro and in vivo. In initial experiments,
we used IMR90 cells since they are easily obtained. We cocul-
tured growing and senescent IMR-90 cells with the NK cells at
1:10 target:effector cell ratio, and cell viability was monitored
by timelapse microscopy and quantified at 12 hr. As a source
of NK cells we used the line YT, which exhibits an NK cell immuno-
phenotype and recognition abilities (Drexler and Matsuo,
2000).
Senescent IMR-90 cells were markedly more sensitive to NK
cell-mediated killing compared to growing cells. Thus, growing
cells were not attacked by YT cells under these coculture condi-
tions and remained attached to the culture dish (Figures 6C and
S9, Movie S1). By contrast, senescent cells readily attracted YT
cells, then underwent apoptosis and detached from the surface
of the dish (Figures 6D and S9, Movie S2).
We next used a quantitative in vitro cytotoxicity assay to test
whether YT cells exhibit cytotoxic activity toward senescent-
activated HSCs. In these studies, activated human HSCs were
made senescent using etoposide treatment and compared to
IMR-90 cells that were triggered to senesce by etoposide, repli-
cative exhaustion, or oncogenic ras (Narita et al., 2003; Serrano
et al., 1997). As assessed by crystal violet staining of cell popu-
lations at 12 hr, senescent cells were much more sensitive to NK-
mediated killing (Figures 6E and 6F, p = 0.0007 for activated
HSCs and p = 0.0002, or p = 0.0008, p = 0.001 for etoposide,Cell 134, 657–667, August 22, 2008 ª2008 Elsevier Inc. 663
replicative exhaustion, or oncogenic ras-induced cells, respec-
tively). Although this selective effect could be overcome at higher
NK cell concentrations (data not shown), these cells can prefer-
entially attack senescent cells in vitro.
To determine whether NK cells can target senescent cells
in vivo and their impact on liver fibrosis, we assessed how mod-
ulating NK cell function would influence the frequency of senes-
cent activated HSCs and fibrosis resolution in livers obtained
from mice following a 6 week course of CCl4 or at various times
after ceasing treatment. To deplete NK cells we treated mice
with neutralizing antibodies (anti-AsialoGM1 [Radaeva et al.,
2006; Xue et al., 2007]) during the period following CCl4
withdrawal. Conversely, to enhance the immune response, we
treated mice with polyinosinic-polycytidylic acid (polyI:C), which
induces interferon-g and enhances NK cell activity in the liver
(Radaeva et al., 2006).
NK cell activity had a dramatic effect on the clearance of se-
nescent cells and resolution of fibrosis. Hence, livers derived
from mice treated with the anti-NK antibody retained many sen-
escent cells and displayed significantly more fibrosis compared
to saline or isotype IgG-treated controls (Figures 7A–7C; data not
shown). Conversely, livers from mice treated with polyI:C for 10
Figure 7. NK Cells Participate in Fibrosis
Reversion and Senescent Cell Clearance
In Vivo
(A) WT mice treated with CCl4 were treated with
either an anti-NK antibody (to deplete NK cells),
polyI:C (as an interferon-g activator), or saline (as
a control) for 10 or 20 days prior to liver harvest.
Liver sections stained for SA-b-gal show positive
cells are retained in fibrotic livers following deple-
tion of NK cells upon treatment with an anti-NK an-
tibody in mice. In contrast, treatment with polyI:C
results in enhanced clearance of senescent cells.
(B) Fibrotic tissue is retained upon depletion of NK
cells as visualized by Sirius Red staining in con-
trast to saline- or polyI:C-treated mice, where it
was depleted more efficiently.
(C) Quantification of fibrosis based on Sirius Red
staining following 10 or 20 days of treatment with
either saline, anti-NK antibody, or polyI:C. Values
are means + SEM. Fibrotic area in anti-NK- or
polyI:C-treated animals was compared to that of
saline-treated animals of corresponding time point
using Student’s t test (*p < 0.05, **p < 0.01).
(D and E) Expression of aSMA in fibrotic livers after
10 days treatment with anti-NK antibody was in-
creased comparing to saline-treated ones, while
its expression was decreased in polyI:C-treated
mice as evaluated by quantitative RT-PCR analy-
sis (D) and immunoblot (E). Values are means +
SEM.
or 20 days contained fewer senescent
cells and less fibrotic tissue compared
to controls. These changes correlated
with the number of activated HSCs pres-
ent since aSMA mRNA and protein levels
were increased following anti-NK anti-
body treatment and decreased following
polyI:C treatment (Figures 7D and 7E). Therefore, the immune
system can effectively eliminate senescent cells from fibrotic
tissue and thereby contribute to the resolution of fibrosis.
DISCUSSION
Fibrosis arises as part of a wound healing response that main-
tains organ integrity following catastrophic tissue damage but
can also contribute to a variety of human pathologies, including
liver cirrhosis (Bataller and Brenner, 2005). In this study, we iden-
tify senescent cells in fibrotic livers of CCl4-treated mice and
show that these arise from activated stellate cells—a cell type
that initially proliferates in response to hepatocyte cell death
and is responsible for the extracellular matrix production that is
the hallmark of the fibrotic scar. Surprisingly, we see that the se-
nescence of activated HSCs limits the accumulation of fibrotic
tissue following chronic liver damage and facilitates the resolu-
tion of fibrosis upon withdrawal of the damaging agent. Thus,
we demonstrate that cellular senescence acts to limit the fibro-
genic response to tissue damage, thereby establishing a role
for the senescence program in pathophysiological settings
beyond cancer.664 Cell 134, 657–667, August 22, 2008 ª2008 Elsevier Inc.
Liver cirrhosis involves dramatic changes in all cellular compo-
nents of the liver, being associated with hepatocyte cell death,
activation of Kupffer cells and HSCs, and the invasion of inflam-
matory cells (Bataller and Brenner, 2005). Previous reports have
identified SA-b-gal-positive cells in cirrhotic livers and sug-
gested that these cells may arise from damaged hepatocytes.
However, the immunotype of senescent cells together with their
location along the fibrotic scar strongly suggests that the major-
ity of these arise from activated HSCs. Furthermore, treatments
that increase or decrease the number of senescent cells in the
liver have an inverse effect on activated HSC accumulation
and fibrosis, and livers from mice lacking the key senescence
regulators display an aberrant expansion of HSCs and enhanced
fibrogenic response. However, our data do not exclude the pos-
sibility that senescent hepatocytes might be present in the liver in
the later stages of liver disease.
Why activated HSCs eventually senesce remains to be deter-
mined. While telomere shortening is the driving force of replica-
tive senescence in cultured human cells (Campisi and d’Adda di
Fagagna, 2007), mouse cells have long telomeres that probably
could not shorten sufficiently to trigger senescence during our 6
week treatment period. By contrast, a similar phenomenon of
proliferation and senescence has been described in the context
of senescence induced by promitogenic oncogenes in both
mouse and human cells (Lin et al., 1998). In some of these set-
tings, senescence is mediated by hyperactive Akt signaling
(Chen et al., 2005), and, indeed, we detected phosphorylated
(active) AKT in activated HSCs present in fibrotic mouse livers
or that had senesced in culture (Figure S10). Although correla-
tive, these results are consistent with the possibility that the se-
nescence of activated HSCs results from the hyperproliferative
signals that trigger their initial expansion.
We have shown that the senescence of activated HSCs pro-
vides a barrier that limits liver fibrosis. The hallmark of cellular se-
nescence is its stable cell-cycle arrest, and indeed, we show that
this process can be triggered acutely in cultured HSCs and is as-
sociated with the downregulation of many cell-cycle-regulated
genes. Undoubtedly, the enforced cell-cycle arrest of activated
HSCs in vivo provides a brake on the fibrogenic response to
damage by limiting the expansion of the cell type responsible
for producing the fibrotic scar.
In addition to halting proliferation, senescent cells—including
the activated HSCs studied here—can also display dramatic
changes in their secretory properties. For example, senescent
cells downregulate genes encoding extracellular matrix compo-
nents and upregulate extracellular matrix-degrading enzymes
(e.g., matrix metalloproteinases), although the biological conse-
quences of these effects have not been considered. In addition,
senescent cells typically upregulate a plethora of genes known
to stimulate immune surveillance. We propose that these
changes contribute in a coordinated way to restrain fibrosis—
on one hand by limiting the secretion of fibrogenic proteins
and degrading those that are present and, on the other, signaling
the immune clearance of the expanded population of activated
HSCs (Figure S11). Thus, senescence represents a homeostatic
mechanism that enables the tissue to return to its predamaged
state. Such a scheme may be broadly relevant to other wound
healing responses.The mechanism of immune clearance of senescent activated
HSCs results from the cytotoxic action of natural killer cells,
although other immune components contribute as well. Hence,
an antagonist of NK cell function delays the clearance of senes-
cence cells and the resolution of fibrosis, whereas an agent that
stimulates the NK cell activation has the opposite effect. Inter-
estingly, a previous report suggested that NK cells might target
a fraction of activated HSCs in fibrotic livers (Radaeva et al.,
2006), though what signaled this attack was not clear. Although
we cannot exclude the possibility that spontaneous apoptosis or
other modes of cell death contribute to the clearance of acti-
vated HSCs in vivo, our studies suggest that, by activating im-
mune surveillance factors, senescent cells identify themselves
to the immune system enabling their efficient clearance—a
process that we show can be recapitulated in vitro. Although a
detailed mechanism remains to be determined, we see that
senescent activated HSCs have significantly higher expression
of MICA, a ligand of NK cell receptor NKG2D. Of note, Rae family
proteins, the NKG2D ligands in mice, are upregulated in re-
sponse to DNA damage (Gasser et al., 2005), which also is a trig-
ger for cellular senescence (Bartkova et al., 2006; Di Micco et al.,
2006; Mallette et al., 2007).
We previously showed that activation of endogenous p53 in
murine liver carcinomas induced senescence and tumor regres-
sion in vivo (Xue et al., 2007). Tumor regression was associated
with an upregulation of inflammatory cytokines and immune
cell adhesion molecules, and several components of the innate
immune system contributed to the clearance of senescent cells.
The demonstration that senescent activated HSCs can be tar-
geted through a similar mechanism further underscores the
fact that, in at least some situations, senescent cells can turn
over in vivo to resolve a tissue pathology. Still, not all senescent
cells may be targets for the immune system, for example, in the
context of benign melanocytic nevi that are stable for years.
Additionally, the accumulation of senescent cells in aged tissues
may be related in part to the established decline in immune sys-
tem function with age. Interestingly, as observed in the mouse
model studied here, clinical data suggest that immunosup-
pressed patients more rapidly progress to liver cirrhosis (Beren-
guer et al., 2000), while immunostimulatory therapy has a protec-
tive effect (Rehermann and Nascimbeni, 2005). Our studies
suggest that immunostimulatory therapy to enhance senescent
cell clearance should be tested for the potential treatment of pa-
tients with liver fibrosis, especially in its early stages or following
short-term exposure to hepatotoxic agents.
We suggest that, following tissue damage, HSCs become ac-
tivated and proliferate intensely, senesce, and are eventually
cleared to protect the liver from an excessive fibrogenic re-
sponse to acute injury. However, in response to chronic tissue
damage, for example, as produced by viral hepatitis or fatty liver
disease, continual rounds of hepatocyte death and HSC prolifer-
ation allow the production of senescent cells to outpace their
clearance, contributing to persistent inflammation and advanc-
ing fibrosis. Such a state, while initially beneficial, may eventually
trigger the aberrant proliferation and transformation of damaged
hepatocytes, leading to cancer. In fact, mixing experiments indi-
cate that senescent fibroblasts can promote the transformation
of premalignant epithelial cells in vivo (Krtolica et al., 2001).Cell 134, 657–667, August 22, 2008 ª2008 Elsevier Inc. 665
Such a model provides one explanation for how cirrhosis predis-
poses to hepatocellular carcinogenesis and may be relevant to
other settings where fibrosis occurs.
EXPERIMENTAL PROCEDURES
Animals
Genotyping protocols of p53/, INK4a/Arf/ and TRE-shp53 mice were pre-
viously described (Dickins et al., 2007; Schmitt et al., 2002). GFAP-tTA mice
were obtained from the Jackson Laboratory. WT, p53/, INK4a/Arf/, and
p53/;INK4a/Arf/ mice were treated twice a week with 12 consecutive
intraperitoneal (i.p.) injections of 1 ml/kg CCl4 to induce liver fibrosis. GFAP-
tTA;TRE-shp53 mice were treated similarly for 2 weeks. Animals were sacri-
ficed 48–72 hr after the last injection and their livers used for further analysis.
To modify NK cell function, mice were treated three times weekly either intra-
venously (i.v.) with an anti-Asialo-GM1 antibody (25 ml in 200 ml saline, Wako,
USA) for 10 or 20 days or i.p. with polyI:C (Sigma, USA) 1 mg/kg. The Cold
Spring Harbor Laboratory Animal Care and Use Committee approved all
procedures described in this work.
Histological Analysis
Paraffin-embedded tissue sections were stained with hematoxylin-eosin for
routine examination or with Sirius Red for visualization of fibrotic deposition.
At least three whole sections from each animal were scanned by Laser Scan-
ner Cytometry (CompuCyte, USA) for fibrosis quantification. These images
were quantified using NIH ImageJ software (http://rsb.info.nih.gov/ij/). We
calculated the amount of fibrotic tissue in diseased animals relative to the
basal amount of Sirius Red staining present in normal liver.
Detection of SA-b-gal activity was performed as described previously (Ser-
rano et al., 1997) at pH = 5.5 for mouse tissue and pH = 6.0 for human cells.
Frozen sections of liver tissue or adherent cells were fixed with 0.5% gluteral-
dehyde in PBS for 15 min, washed with PBS supplemented with 1 mM MgCl2,
and stained for 5–6 hr in PBS containing 1 mM MgCl2, 1mg/ml X-Gal, and
5 mM of each potassium ferricyanide and potassium ferrocyanide. Sections
were counterstained with Eosin.
Immunostaining was performed as previously described (Xue et al., 2007).
The following antibodies were used: Ki67 (Dianova, Germany), p21 (BD Phar-
Mingen, USA), aSMA (DakoCytomation, Denmark), p16, p53, Desmin, and
GFAP (all from Santa Cruz, USA). Anti-HMGA1 antibodies were raised in rab-
bits immunized with peptide corresponding to amino acids 79 to 94 in HMGA1
protein and found to be reactive with HMGA1 (and not crossreactive with
HMGA2) (Narita et al., 2006). AlexaFluor-conjugated secondary antibodies
were used for signal detection.
Electron Microscopy
Samples of mouse liver were fixed, dehydrated, and embedded in Epon-
Araldite (Electron Microscopy Sciences, USA). Sections were contrasted
and imaged in a Hitachi H7000T transmission electron microscope.
Tissue Culture
Human IMR-90 fibroblasts (ATCC) and primary human hepatic myofibroblasts
(activated HSCs) (Dominion Pharmakine, Spain) were grown in standard con-
ditions (Narita et al., 2003). Senescence was induced by prolonged culturing,
etoposide (100 mM, Sigma) treatment, or infection of IMR-90 cells with onco-
genic rasV12 as described (Narita et al., 2003). For in vitro cytotoxicity assays,
growing or senescent cells were plated in 6-well plates at 50,000 cells per well.
5 3 105 YT cells (from DSMZ, Germany) were subsequently added to target
cells. The plates were incubated under normal conditions for 12 hr, and then
NK cell cytotoxicity was determined using crystal violet staining of remaining
adherent cells or followed with a Zeiss AxioObserver microscope equipped
with 37C incubator hood and 6.3% CO2 cover.
Immunoblotting
Liver tissue was lysed in Laemmli buffer using a tissue homogenizer. Equal
amounts of protein were separated on 12% SDS-polyacrylamide gels and666 Cell 134, 657–667, August 22, 2008 ª2008 Elsevier Inc.transferred to PVDF membranes. Detection was performed using anti-aSMA
(DakoCytomation) and anti-b-actin (AC-15, Sigma).
Expression Array Analysis and Quantitative RT-PCR
RNA preparation, cDNA synthesis, and quantitative PCR were performed as
described previously (Xue et al., 2007). Affymetrix Human Genome U133
Plus 2.0 Array was used to identify genes expressed in HSC. Gene Ontology
(GO) (http://www.geneontology.org/) and KEGG pathway (http://www.
genome.jp/kegg/pathway.html) analysis was performed on upregulated and
downregulated genes using g:Profiler web tool (http://biit.cs.ut.ee/gprofiler/).
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